Tirzepatide has the advantage of current FDA approval, while Retatrutide requires obtaining through research channels until approved
Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
Melanotan-1 (afamelanotide) operates through melanocortin-1 receptor (MC1R) agonism, which triggers eumelanin synthesis in melanocytes
Supplements are not the same as prescription hormone therapy, and they are not held to the same standards for safety, dosing, or effectiveness
Gibson credited natural remedies and a special diet with curing her cancer